pediatric - Page 1 | CARLAT PUBLISHING

Expert Q&A

Crisis in Pediatric Mental Health: The Kids Aren’t Alright

August 1, 2023

Warren Y.K. Ng, MD.

Child and adolescent psychiatrist; Medical Director of Clinical Services, Division of Child and Adolescent Psychiatry, Columbia University Medical Center and New York Presbyterian/Morgan Stanley Children’s Hospital; President, American Academy of Child and Adolescent Psychiatry, New York, NY.

Dr. Ng has no financial relationships with companies related to this material.

As the head of the American Academy of Child & Adolescent Psychiatry, Dr. Ng is deeply familiar with the serious issues facing pediatric mental health. He outlines methods to protect children, such as partnering with pediatricians and making use of school-based programs. Additionally, he lists resources for healthcare providers, patients, and their families.

Clinical Update

Psychiatric Consultation to Children and Adolescents on Pediatric Units: A Primer

August 1, 2023

Jessica E. Becker, MD, MPH. and Joshua Smith, MD.

Jessica E. Becker, MD, MPH. Department of Child and Adolescent Psychiatry, NYU Grossman School of Medicine, NYU Langone Health, New York, NY.

Joshua Smith, MD. Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, TN.

Dr. Becker is an awardee of the American Academy of Child and Adolescent Psychiatry (AACAP) Junior Investigator Award, which is funded by AACAP and industry sponsors. Relevant financial relationships listed for the author have been mitigated.

Dr. Smith has no financial relationships with companies related to this material.

Pediatric consultation-liaison (C-L) psychiatry is a field that combines psychiatry, pediatrics, and child development. We’ll give you pointers on how to manage pediatric C-L psychiatry consults, with specific recommendations for different age groups.

Transcranial Magnetic Stimulation (TMS) for Depression in Children and Adolescents

June 11, 2019

With concerns about both safety and efficacy surrounding antidepressant use in children and adolescents, we are always looking for safe, effective treatments for our patients. Transcranial Stimulation (TMS) has been around for many years, and its use in youth is expanding. We examine the evidence of efficacy and potential side effects in youth and adolescent populations.

Medications for Depression

June 11, 2019

Martha J. Ignaszewski, MD

Martha J. Ignaszewski, MD

Chief Fellow, Clinical Fellow in Psychiatry at Boston Children’s Hospital

Dr. Ignaszewski has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

In this QA, we review the findings of placebo- controlled trials done over the past 10 years on depression in kids and the discuss the current recommendations for medication treatment of depression in children and adolescents.

Practical Approaches to Vetting Clinical Research

June 11, 2019

Darren B. Courtney, MD, FRCPC

Darren B. Courtney, MD, FRCPC

Staff Psychiatrist for the Youth Addictions and Concurrent Disorders Service at the Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada

Dr. Courtney has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

In this QA, we discuss how to use the PICOT method to efficiently frame the clinical questions that arise in everyday practice. We also examine the hierarchy in terms of the types of studies that are most useful for the busy clinician to look at and provide a corresponding table covering the categories of evidence for clinical practice.

FDA Approves Adhansia XR

June 11, 2019

Talia Puzantian, PharmD, BCPP and Joshua Feder, MD

Talia Puzantian, PharmD, BCPP Joshua Feder, MD Drs. Puzantian and Feder have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

In this article we discuss a newly FDA-approved formulation for ADHD. Adhansia XR, is a new formulation of extended-release methylphenidate approved by the FDA for the treatment of ADHD in patients 6 years and older.

First Non-Drug Treatment Approved by FDA for Treating Children With ADHD

June 11, 2019

Talia Puzantian, PharmD, BCPP and Joshua Feder, MD

Talia Puzantian, PharmD, BCPP Joshua Feder, MD Drs. Puzantian and Feder have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

In the article we discuss the effectiveness and safety of the first non-drug treatment for ADHD in kids. The FDA has recently granted medical device approval for its external Monarch Trigeminal Nerve Stimulation (eTNS) System for treating kids with ADHD ages 7–12 who are not currently taking medications.

Steroid-Induced Psychosis in the Pediatric Population

June 11, 2019

Ahhan Nazeer, MD.

Ahhan Nazeer, MD. Dr. Nazeer has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Although childhood psychosis is a rare disorder, an accurate diagnosis is crucial. This article analyzes the results of a 2019 case study of steroid-induced psychosis in a pediatric patient.

Risk of Psychosis With Stimulants in ADHD Patients

June 11, 2019

Pavan Madan, MD

Pavan Madan, MD Dr. Madan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

As of 2007, the FDA requires stimulant manufacturers to warn of possible psychosis with stimulant use. This article analyzes the results of a 2019 study comparing the risk of psychosis between methylphenidate and amphetamine classes of medications.